בריפלקס PN 250

Country: Իսրայել

language: եբրայերեն

source: Ministry of Health

active_ingredient:

COAGULATION FACTOR II (HUMAN); COAGULATION FACTOR IX (HUMAN- RFIXFC); COAGULATION FACTOR VII (HUMAN); COAGULATION FACTOR X (HUMAN); PROTEIN C; PROTEIN S ANTIGEN

MAH:

CSL BEHRING LTD., ISRAEL

ATC_code:

B02BD01

pharmaceutical_form:

אבקה וממס להכנת תמיסה להזרקה

composition:

COAGULATION FACTOR II (HUMAN) 200 - 480 IU; COAGULATION FACTOR VII (HUMAN) 100 - 250 IU; COAGULATION FACTOR IX (HUMAN- RFIXFC) 200 - 310 IU; COAGULATION FACTOR X (HUMAN) 220 - 600 IU; PROTEIN C 150 - 450 IU; PROTEIN S ANTIGEN 120 - 380 IU

administration_route:

תוך-ורידי

prescription_type:

מרשם נדרש

manufactured_by:

CSL BEHRING GmbH, GERMANY

therapeutic_group:

COAGULATION FACTOR IX, II, VII AND X IN COMBINATION

therapeutic_area:

COAGULATION FACTOR IX, II, VII AND X IN COMBINATION

therapeutic_indication:

-Treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required.

authorization_date:

2017-03-31